Boosting ADR Reporting: Assessing Knowledge, Attitude, and Practices Among UAE Hospital Pharmacists

By Staff Writer

August 2, 2023

A recent study aimed to evaluate the knowledge, attitudes, and practices (KAP) of hospital pharmacists in the UAE regarding Adverse Drug Reaction (ADR) reporting and the barriers to implementing a Pharmacovigilance (PV) system.

Although pharmacists generally display a positive attitude towards ADR reporting, the level of reporting remains low, which may be due to a lack of knowledge about PV and ADRs, including what, where, and when to report.

Interestingly, findings showed that gender does not affect awareness of PV and ADR reporting, but educational level and years of experience do. Hospital pharmacists with less than five years of experience lack the expertise of those with 10-14 years of experience in PV and ADR reporting.

Despite observing ADRs, only half of the participants reported them. This underreporting could be due to poor time management, lack of awareness of the reporting process, difficulties in accessing ADR reports, and poor patient-pharmacist communication.

They also found that the role and years of experience influence the likelihood of ADR reporting. Clinical pharmacists and inpatient pharmacists are more likely to engage in PV due to their direct patient care experience.

In terms of barriers, over half of the pharmacists cited a lack of knowledge about the reporting process. Fear of repercussions from management and legal culpability were also mentioned.

To improve ADR reporting, they recommend incentives for reporting, conducting workshops and ongoing education, providing legal protection, and ensuring easy online access to ADR forms.

Reference url

Recent Posts

masitinib prostate cancer trial
        

Masitinib Prostate Cancer Trial Gains FDA and EMA Approval for Phase 3 Study

🚀 What’s the next big thing in prostate cancer treatment?

The recent FDA and EMA authorizations for the masitinib prostate cancer trial could revolutionize care for metastatic castrate-resistant prostate cancer (mCRPC). This groundbreaking study employs a biomarker-driven strategy to optimize treatment outcomes for patients like never before!

Dive into the full article to explore the implications of this targeted therapy and how it may change the future of precision medicine in oncology.

#SyenzaNews #Oncology #PrecisionMedicine #HealthTech

BEBT-908 DLBCL treatment
        

BEBT-908 DLBCL Treatment: A Milestone Approval for a First-in-Class Dual Inhibitor in China

🚀 Are we on the brink of a revolution in DLBCL treatment?

The recent conditional approval of **BEBT-908** by China’s National Medical Products Administration is not just a milestone for oncology, but potentially a game-changer for adults battling relapsed or refractory diffuse large B-cell lymphoma. With its dual-target mechanism, this first-in-class therapy offers promising efficacy and a well-thought-out access strategy that could reshape treatment standards.

Dive into the full article to discover how BEBT-908 is setting new benchmarks in both clinical outcomes and healthcare affordability.

#SyenzaNews #oncology #pharmaceuticals #MarketAccess

AI Cost Implications
    

AI Clinician in Pediatric ICU: A Review and HEOR Perspective

🤖 What could AI Clinician support mean for pediatric ICU care?

A new collaboration between Imperial College London and CHOC is developing an AI system to guide treatment decisions in PICUs. This article reviews the initiative and examines its broader health system implications—offering a Health Economics and Outcomes Research (HEOR) perspective on how AI may shape efficiency, equity, and value in critical care.

Read on to explore how clinical innovation intersects with healthcare economics.

#SyenzaNews #AIinHealthcare #HEOR #PediatricCare #HealthInnovation #PICU

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER

© 2025 Syenza™. All rights reserved.